GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BGI Genomics Co Ltd (SZSE:300676) » Definitions » Net Income

BGI Genomics Co (SZSE:300676) Net Income : ¥64 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is BGI Genomics Co Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. BGI Genomics Co's Net Income for the three months ended in Mar. 2024 was ¥12 Mil. Its Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was ¥64 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. BGI Genomics Co's Earnings per Share (Diluted) for the three months ended in Mar. 2024 was ¥0.03.


BGI Genomics Co Net Income Historical Data

The historical data trend for BGI Genomics Co's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BGI Genomics Co Net Income Chart

BGI Genomics Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 276.33 2,090.29 1,461.54 802.77 92.90

BGI Genomics Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 41.21 10.53 18.61 22.55 12.40

BGI Genomics Co Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

BGI Genomics Co's Net Income for the fiscal year that ended in Dec. 2023 is calculated as

Net Income(A: Dec. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=115.536+-21.854+0+-0.782
=93

BGI Genomics Co's Net Income for the quarter that ended in Mar. 2024 is calculated as

Net Income(Q: Mar. 2024 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=16.038+-3.888+0+0.253
=12

Net Income for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥64 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BGI Genomics Co  (SZSE:300676) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

BGI Genomics Co's Earnings per Share (Diluted) (EPS) for the quarter that ended in Mar. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


BGI Genomics Co Net Income Related Terms

Thank you for viewing the detailed overview of BGI Genomics Co's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


BGI Genomics Co (SZSE:300676) Business Description

Traded in Other Exchanges
N/A
Address
21 Hongan Third Street, Dong, Huada Complex Park, Yantian District, Shenzhen, CHN, 518083
BGI Genomics Co Ltd is a China-based company principally engaged in the provision of genomic class diagnosis and research services through the application of biotechnology. It offers its services in various research areas, such as agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug discovery. The company mainly provides services for domestic and overseas academic institutions hospitals, medical institutions and others.
Executives
Wang Jian Director
Liu Na Executives
Sun Ying Jun Director
Yin Ye Directors, executives
Du Yu Tao Directors, executives
Li Song Gang Supervisors
Hu Yu Jie Supervisors
Xu Qian Secretary Dong
Li Zhi Ping Executives
Chen Yi Qing Executives
Li Wen Qi Supervisors

BGI Genomics Co (SZSE:300676) Headlines

No Headlines